Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.

Nadeau BA, Fecher LA, Owens SR, Razumilava N.

Semin Liver Dis. 2018 Nov;38(4):366-378. doi: 10.1055/s-0038-1667358. Epub 2018 Oct 24. Review.

PMID:
30357774
2.

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.

Rizzo JM, Fecher LA, Chan MP, Durham AB.

JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May. No abstract available.

3.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

4.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. Erratum in: J Clin Invest. 2018 Apr 2;128(4):1708.

5.

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab.

Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD.

J Immunother Cancer. 2017 Mar 6;5:27. doi: 10.1186/s40425-017-0221-x. eCollection 2017.

6.

Metastatic Merkel cell carcinoma response to nivolumab.

Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD.

J Immunother Cancer. 2016 Nov 15;4:79. eCollection 2016. Erratum in: J Immunother Cancer. 2017 Mar 6;5:27.

7.

Acute visual loss after ipilimumab treatment for metastatic melanoma.

Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LA.

J Immunother Cancer. 2016 Oct 18;4:66. eCollection 2016.

8.

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Fecher LA, Sharfman WH.

Biologics. 2015 Nov 6;9:129-40. doi: 10.2147/BTT.S54179. eCollection 2015. Review.

9.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

10.

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.

Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, Katona TM, Warren S, Logan TF, Fecher LA, Cheng L.

Mod Pathol. 2015 Apr;28(4):480-6. doi: 10.1038/modpathol.2014.136. Epub 2014 Nov 7.

11.

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.

Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK.

Autophagy. 2014 Aug;10(8):1369-79. doi: 10.4161/auto.29118. Epub 2014 May 20.

12.

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.

Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK.

Autophagy. 2014 Aug;10(8):1391-402. doi: 10.4161/auto.29119. Epub 2014 May 20.

13.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

14.

Ipilimumab and its toxicities: a multidisciplinary approach.

Fecher LA, Agarwala SS, Hodi FS, Weber JS.

Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17. Review.

15.

Systemic therapy for inoperable and metastatic basal cell cancer.

Fecher LA.

Curr Treat Options Oncol. 2013 Jun;14(2):237-48. doi: 10.1007/s11864-013-0233-9.

PMID:
23558911
16.

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD.

J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.

17.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA.

Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012 Jul 16.

18.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA.

Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16.

PMID:
22805291
19.

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.

J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.

20.

Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.

Clin Cancer Res. 2009 Jul 1;15(13):4277-87. doi: 10.1158/1078-0432.CCR-09-0537. Epub 2009 Jun 23.

21.

Drug targeting of oncogenic pathways in melanoma.

Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT.

Hematol Oncol Clin North Am. 2009 Jun;23(3):599-618, x. doi: 10.1016/j.hoc.2009.03.004. Review.

PMID:
19464605
22.

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

Fecher LA, Flaherty KT.

J Natl Compr Canc Netw. 2009 Mar;7(3):295-304. Review.

PMID:
19401062
23.

Effectively targeting BRAF in melanoma: a formidable challenge.

Fecher LA, Amaravadi R, Schuchter LM.

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x. No abstract available.

PMID:
18710372
24.

The MAPK pathway in melanoma.

Fecher LA, Amaravadi RK, Flaherty KT.

Curr Opin Oncol. 2008 Mar;20(2):183-9. doi: 10.1097/CCO.0b013e3282f5271c. Review.

PMID:
18300768
25.

Toward a molecular classification of melanoma.

Fecher LA, Cummings SD, Keefe MJ, Alani RM.

J Clin Oncol. 2007 Apr 20;25(12):1606-20. Review.

PMID:
17443002

Supplemental Content

Loading ...
Support Center